Molecular Insight taps Wallroth as CFO

TriMed Staff | | Health Imaging | Artificial Intelligence
Radiotherapeutic molecular medicine developer Molecular Insight Pharmaceuticals has named Donald Wallroth as its chief financial officer (CFO). Wallroth joins the Cambridge, Mass.-based Molecular Insight from the national life sciences practice of Tatum, an executive financial services firm.

Prior to joining Tatum, Wallroth held executive financial management positions with Keen Partners, GoldK, Transition Systems, Project Software and Development, Accenture, and Arthur D. Little, according to Molecular Insight.

TriMed Staff

Related Content

Experts highlight 'significant concerns' with fluctuating accuracy of popular large language models
FDA clears AI screening tool for cardiac amyloidosis
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Deep learning reconstruction cuts radiation and contrast dose by half in aortic CTA exams
New study highlights the need to include more challenging datasets in AI training

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.